选择性氨基酸配方增强阴离子分泌并恢复囊性纤维化突变的功能
Astrid Grosche1, Anusree Sasidharan1, Matthias Salathe2
1Department of Radiation Oncology, University of Florida, Gainesville, FL, United States.
Frontiers in pharmacology
|August 20, 2025
概括
一种新的选择性氨基酸配方 (SAA) 增强了囊性纤维化 (CF) 细胞中的离子分泌,不论突变类型如何. 这种SAA疗法有望改善CFTR功能和呼吸道表面液体平衡.
科学领域:
- 细胞生物学
- 呼吸系统医学
- 生物化学
背景情况:
- 囊性纤维化 (CF) 涉及CFTR突变导致阴离子分泌受损和呼吸道表面液体 (ASL) 不平衡.
- 目前的CFTR调节剂 (VX) 对I类突变无效,可能会产生副作用.
- 其他离子通道 (ANO1,SLC26A9) 和氨基酸配方可以影响离子通道功能.
研究的目的:
- 开发和评估一种精选的氨基酸配方 (SAA),用于增强CF支气管上皮细胞中的离子分泌.
- 确定SAA在不同CFTR突变类 (I和II) 的疗效.
- 评估SAA对ASL恒温标志物的影响,如体积和眼跳动频率.
主要方法:
- 在野生型和CF人类支气管上皮细胞 (HBEC) 中测量了CFTR类I/II突变.
- 使用SAA处理和顺序通道抑制的室内实验 (例如,本扎米尔).
- 评估化物流量,离子通道表达 (mRNA/蛋白质),ASL体积和动频率 (CBF).
主要成果:
- 在CF-HBEC (I和II类) 中,SAA显著增加了对胺不敏感的电流和净化物分泌量 (JnetCl),接近野生型水平.
- 通过增加mRNA和膜蛋白表达,SAA增强了SLC26A9的活性,并促进了部分CFTR的恢复.
- 在CF模型中,SAA改善了ASL体积和CBF,包括I类突变.
结论:
- 选择氨基酸配方 (SAA) 通过调节SLC26A9和CFTR有效增强阴离子分泌.
- 对于CF来说,SAA是一种不依赖突变的治疗策略,对I类突变特别有益.
- 在囊性纤维化患者中,SAA有可能改善阴离子分泌和临床结果.
更多相关视频
相关概念视频
Cystic Fibrosis: Management
220
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
220
Cystic Fibrosis: Pathogenesis
358
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
358
Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
Sulfur Assimilation
72
Sulfur is an essential element in biological systems, contributing to synthesizing key biomolecules, including amino acids such as cysteine and methionine, and cofactors such as coenzyme A and biotin. Microorganisms primarily assimilate sulfur as sulfate (SO₄²⁻) from the environment, which must undergo a series of biochemical transformations before it can be incorporated into cellular components. As sulfate is highly oxidized, it must undergo assimilatory sulfate reduction to...
72
Antiasthma Drugs: Leukotriene Modifiers
453
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
453


